{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:46:30Z","timestamp":1782798390431,"version":"3.54.5"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hypomethylating agents, particularly azacitidine and decitabine, are widely used for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Gastrointestinal adverse events and metabolism- and nutrition-related disorders may compromise nutritional intake, metabolic homeostasis, treatment tolerance, and clinical outcomes. However, real-world evidence regarding these safety profiles remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to characterize gastrointestinal and metabolism- and nutrition-related adverse event reporting signals associated with azacitidine and decitabine, examine cross-database signal consistency, assess exploratory time-to-onset patterns, and explore potential mechanistic clues.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>FAERS reports from database inception through 2025 Q4 were analyzed for azacitidine and decitabine recorded as suspected drugs. Disproportionality was assessed at the preferred-term level using reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and multi-item gamma Poisson shrinker methods. Selected signals were examined in the Canada Vigilance database for cross-database signal consistency. Exploratory time-to-onset patterns were evaluated using Weibull modeling among reports with valid date information, and network toxicology was conducted as a hypothesis-generating analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fourteen thousand two hundred sixteen azacitidine-related reports and 3,591 decitabine-related reports were included. Neutropenic colitis showed the strongest gastrointestinal disproportionality signal for azacitidine and decitabine, with reporting odds ratios of 23.65 and 26.05, respectively. Tumor lysis syndrome was the most prominent metabolism- and nutrition-related signal, with 165 azacitidine-related reports and 47 decitabine-related reports. Both signals showed consistent disproportional reporting patterns in the Canada Vigilance database. Additional signals included iron overload, hypoalbuminemia, electrolyte disturbances, cachexia, failure to thrive, and decreased appetite. Time-to-onset analysis suggested an early reporting tendency among reports with valid date information. Exploratory network toxicology identified 45 common targets, including\n                      <jats:italic>MMP9, PTGS2, CASP3, GSK3B<\/jats:italic>\n                      , and\n                      <jats:italic>ADAM17<\/jats:italic>\n                      , suggesting potential involvement of inflammation, apoptosis, matrix remodeling, nitrogen metabolism, folate biosynthesis, lipid metabolism, and insulin resistance pathways.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Azacitidine and decitabine showed clinically relevant gastrointestinal, metabolic, and nutrition-related disproportionality reporting signals in spontaneous reporting databases. Early monitoring of gastrointestinal symptoms, electrolyte balance, tumor lysis indicators, albumin levels, appetite, and iron metabolism may support nutritional risk management and individualized supportive care in patients receiving hypomethylating agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnut.2026.1865637","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:37:15Z","timestamp":1782797835000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Gastrointestinal adverse reactions and metabolism\u2013nutrition disorders associated with hypomethylating agents: a pharmacovigilance study with exploratory mechanistic analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Mei","family":"Xiang","sequence":"first","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang","place":["Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang","place":["Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang","place":["Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang","place":["Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang","place":["Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang","place":["Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixiong","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang","place":["Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang","place":["Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang","place":["Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1053\/j.seminhematol.2025.06.003","article-title":"Epigenetic dysregulation in acute myeloid leukemia","volume":"62","author":"Schrezenmeier","year":"2025","journal-title":"Semin Hematol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3390\/biom15060761","article-title":"Myelodysplastic Neoplasms (MDS): pathogenesis and therapeutic prospects","volume":"15","author":"Li","year":"2025","journal-title":"Biomolecules"},{"key":"B3","doi-asserted-by":"publisher","first-page":"897898","DOI":"10.3389\/fonc.2022.897898","article-title":"Whole-genome DNA methylation sequencing reveals epigenetic changes in myelodysplastic syndromes","volume":"12","author":"Zhou","year":"2022","journal-title":"Front Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/ajh.26667","article-title":"Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: past discoveries and future directions","volume":"97","author":"Short","year":"2022","journal-title":"Am J Hematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1182\/blood.2024025648","article-title":"Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm","volume":"144","author":"Hunter","year":"2024","journal-title":"Blood."},{"key":"B6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41408-022-00770-x","article-title":"Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis","volume":"12","author":"Kwag","year":"2022","journal-title":"Blood Cancer J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"10843","DOI":"10.1038\/s41598-021-90403-3","article-title":"Efficacy, safety and tolerability of drugs studied in phase 3 randomized controlled trials in solid tumors over the last decade","volume":"11","author":"Ribnikar","year":"2021","journal-title":"Sci Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1159\/000543519","article-title":"A real-world pharmacovigilance analysis for demethylation drug: findings from the FDA adverse event reporting database","volume":"103","author":"Zeng","year":"2025","journal-title":"Oncology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41375-020-1003-x","article-title":"Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network","volume":"35","author":"Gu","year":"2021","journal-title":"Leukemia."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1158\/1078-0432.CCR-21-4525","article-title":"FDA approval summary: oral azacitidine for continued treatment of adults with acute myeloid leukemia unable to complete intensive curative therapy","volume":"28","author":"Jen","year":"2022","journal-title":"Clin Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s40265-020-01389-7","article-title":"Decitabine\/cedazuridine: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2026.04.038","article-title":"Emerging safety signals of sonidegib Hedgehog inhibition for basal cell carcinoma: a real-world analysis from the FDA adverse event reporting system (FAERS)","author":"Mahajan","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001"},{"key":"B15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1555838","DOI":"10.3389\/fphar.2025.1555838","article-title":"The real-world analysis of adverse events with azacitidine: a pharmacovigilance study based on the FAERS and WHO-VigiAccess databases","volume":"16","author":"Wang","year":"2025","journal-title":"Front Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.clml.2023.01.007","article-title":"Sex disparities in myelodysplastic syndromes: genotype, phenotype, and outcomes","volume":"23","author":"Tinsley-Vance","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1038\/s41375-024-02435-z","article-title":"Bullinger L. Acute myeloid leukemia: does sex matter?","volume":"38","author":"Tettero J","year":"2024","journal-title":"Leukemia."},{"key":"B19","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jama.2022.14578","article-title":"Diagnosis and treatment of myelodysplastic syndromes: a review","volume":"328","author":"Sekeres","year":"2022","journal-title":"JAMA."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e22328","DOI":"10.1136\/bmjopen-2018-022328","article-title":"Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China","volume":"8","author":"Guan","year":"2018","journal-title":"BMJ Open."},{"key":"B21","doi-asserted-by":"publisher","first-page":"100944","DOI":"10.1016\/j.blre.2022.100944","article-title":"Recent advances in neutropenic enterocolitis: insights into the role of gut microbiota","volume":"54","author":"Kapandji","year":"2022","journal-title":"Blood Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.14740\/jh1105","article-title":"Neutropenic enterocolitis: an uncommon, but fearsome complication of leukemia","volume":"12","author":"Babakhanlou","year":"2023","journal-title":"J Hematol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"114644","DOI":"10.1016\/j.biopha.2023.114644","article-title":"Review on the effect of chemotherapy on the intestinal barrier: epithelial permeability, mucus and bacterial translocation","volume":"162","author":"Dahlgren","year":"2023","journal-title":"Biomed Pharmacother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"681417","DOI":"10.3389\/fphar.2021.681417","article-title":"Chemotherapeutics-induced intestinal mucositis: pathophysiology and potential treatment strategies","volume":"12","author":"Dahlgren","year":"2021","journal-title":"Front Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1093\/cid\/ciaf134","article-title":"Epidemiology, risk factors, and outcomes of neutropenic enterocolitis in onco-hematological patients according to chemotherapy regimen","volume":"82","author":"Brunel","year":"2026","journal-title":"Clin Infect Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"108232","DOI":"10.1016\/j.leukres.2026.108232","article-title":"Risk factors and fluid management in tumor lysis syndrome of acute myeloid leukemia: a retrospective study","volume":"166","author":"Yuan","year":"2026","journal-title":"Leuk Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3390\/biomedicines10051012","article-title":"Tumor lysis syndrome: an endless challenge in onco-nephrology","volume":"10","author":"Lupu\u015foru","year":"2022","journal-title":"Biomedicines"},{"key":"B28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41392-023-01342-6","article-title":"Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct Target Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.clinthera.2025.08.001","article-title":"Anticancer drugs associated with tumor lysis syndrome: insights from the US food and drug administration adverse event reporting system","volume":"47","author":"Wang","year":"2025","journal-title":"Clin Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"627662","DOI":"10.3389\/fimmu.2020.627662","article-title":"The clinical significance of iron overload and iron metabolism in myelodysplastic syndrome and acute myeloid leukemia","volume":"11","author":"Weber","year":"2020","journal-title":"Front Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"8855038","DOI":"10.1155\/2020\/8855038","article-title":"Iron overload impairs bone marrow mesenchymal stromal cells from higher-risk MDS patients by regulating the ROS-related Wnt\/\u03b2-catenin pathway","volume":"2020","author":"Huang","year":"2020","journal-title":"Stem Cells Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s12185-017-2367-1","article-title":"Iron overload in myelodysplastic syndromes (MDS)","volume":"107","author":"Gattermann","year":"2018","journal-title":"Int J Hematol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/SPC.0000000000000762","article-title":"Cancer cachexia: exploring parallels with other paraneoplastic syndromes","volume":"19","author":"Yule","year":"2025","journal-title":"Curr Opin Support Palliat Care."},{"key":"B34","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"Dinardo","year":"2020","journal-title":"N Engl J Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1016\/j.cell.2024.05.001","article-title":"Time-resolved fate mapping identifies the intestinal upper crypt zone as an origin of Lgr5+ crypt base columnar cells","volume":"187","author":"Capdevila","year":"2024","journal-title":"Cell."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1078031","DOI":"10.3389\/fimmu.2023.1078031","article-title":"Mapping of DNA methylation-sensitive cellular processes in gingival and periodontal ligament fibroblasts in the context of periodontal tissue homeostasis","volume":"14","author":"Lagosz-Cwik","year":"2023","journal-title":"Front Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3390\/pharmaceutics17040479","article-title":"Applications of matrix metalloproteinase-9-related nanomedicines in tumors and vascular diseases","volume":"17","author":"Li","year":"2025","journal-title":"Pharmaceutics"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1038\/s44318-024-00108-2","article-title":"Decitabine cytotoxicity is promoted by dCMP deaminase DCTD and mitigated by SUMO-dependent E3 ligase TOPORS","volume":"43","author":"Carnie","year":"2024","journal-title":"EMBO J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.tem.2023.06.002","article-title":"Extracellular vesicle-mediated interorgan communication in metabolic diseases","volume":"34","author":"Hu","year":"2023","journal-title":"Trends Endocrinol Metab."},{"key":"B40","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.leukres.2011.11.024","article-title":"Proteomic analysis identifies differentially expressed proteins in AML1\/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine","volume":"36","author":"Buchi","year":"2012","journal-title":"Leuk Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"102891","DOI":"10.1016\/j.arr.2025.102891","article-title":"TNF as a mediator of metabolic inflammation and body-brain interaction in obesity-driven neuroinflammation and neurodegeneration","volume":"112","author":"Lo","year":"2025","journal-title":"Ageing Res Rev."},{"key":"B42","doi-asserted-by":"publisher","first-page":"674720","DOI":"10.3389\/fonc.2021.674720","article-title":"Targeting amino acid metabolic vulnerabilities in myeloid malignancies","volume":"11","author":"Fultang","year":"2021","journal-title":"Front Oncol."}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1865637\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:37:16Z","timestamp":1782797836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1865637\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":42,"alternative-id":["10.3389\/fnut.2026.1865637"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2026.1865637","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"article-number":"1865637"}}